Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.

Michael B AtkinsBrian I RiniRobert J MotzerThomas PowlesDavid F McDermottCristina SuarezSergio BracardaWalter M StadlerFrede DonskovHoward GurneyStephane OudardMotohide UemuraElaine T LamCarsten GrüllichSusheela CarrollBeiying DingQian Cindy ZhuElisabeth Piault-LouisChristina SchiffBernard Escudier

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

PROs in IMmotion151 suggest lower overall treatment burden with atezolizumab plus bevacizumab compared with sunitinib in patients with treatment-naïve mRCC and provide further evidence for clinical benefit of this regimen.

Keyphrases

phase iii
metastatic renal cell carcinoma
open label
patient reported outcomes
clinical trial
double blind
phase ii
randomized controlled trial
placebo controlled